Sungyeun Bae

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 9

Top Topics

Clinical Evaluation

Coronary Artery

Bariatric Surgery

Top Venues

Clinical and translational science

Drug design, development and therapy

Pharmaceuticals (Basel, Switzerland)

Translational and clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Xu Jiang, Sungyeun Bae, Deok Yong Yoon, Shin Jung Park, Jaeseong Oh, Joo-Youn Cho, Kyung-Sang Yu
Comparison of the Pharmacokinetics, Safety, and Tolerability of Two Empagliflozin Formulations in Healthy Korean Subjects. Drug design, development and therapy 17 (2023)
Min Young Park, Sungyeun Bae, Jung A Heo, Mihee Park, YuKyung Kim, Jumi Han, In-Jin Jang, Kyung-Sang Yu, Jaeseong Oh
Safety, tolerability, pharmacokinetic/pharmacodynamic characteristics of bersiporocin, a novel prolyl-tRNA synthetase inhibitor, in healthy subjects. Clinical and translational science (2023)
Min Young Park, Sungyeun Bae, Jung A Heo, Mihee Park, YuKyung Kim, Jumi Han, In-Jin Jang, Kyung-Sang Yu, Jaeseong Oh
Safety, tolerability, pharmacokinetic/pharmacodynamic characteristics of bersiporocin, a novel prolyl-tRNA synthetase inhibitor, in healthy subjects. Clinical and translational science (2023)
Sungyeun Bae, Jihoon Kwon, Mi-Hye Lee, Kyung-Sang Yu, Seung Hwan Lee
Development of a Fast Onset Proton Pump Inhibitor: Comparison of Fixed-Dose Combination of Rabeprazole and Sodium Bicarbonate (YPI-011) to the Conventional Enteric-Coated Rabeprazole. Drug design, development and therapy 17 (2023)
Sungyeun Bae, Ki Young Huh, Jaeseong Oh, Kyung-Sang Yu, Anhye Kim
Evaluation of Safety, Tolerability and Pharmacokinetic Characteristics of SA001 and Its Active Metabolite Rebamipide after Single and Multiple Oral Administration. Pharmaceuticals (Basel, Switzerland) 16 (1) (2023)
Sungyeun Bae, Ki Young Huh, Jaeseong Oh, Kyung-Sang Yu, Anhye Kim
Evaluation of Safety, Tolerability and Pharmacokinetic Characteristics of SA001 and Its Active Metabolite Rebamipide after Single and Multiple Oral Administration. Pharmaceuticals (Basel, Switzerland) 16 (1) (2023)
Min Young Park, Sungyeun Bae, Jung A Heo, Mihee Park, YuKyung Kim, Jumi Han, In-Jin Jang, Kyung-Sang Yu, Jaeseong Oh
Safety, tolerability, pharmacokinetic/pharmacodynamic characteristics of bersiporocin, a novel prolyl-tRNA synthetase inhibitor, in healthy subjects. Clinical and translational science (2023)
Sungyeun Bae, Jihoon Kwon, Mi-Hye Lee, Kyung-Sang Yu, Seung Hwan Lee
Development of a Fast Onset Proton Pump Inhibitor: Comparison of Fixed-Dose Combination of Rabeprazole and Sodium Bicarbonate (YPI-011) to the Conventional Enteric-Coated Rabeprazole. Drug design, development and therapy 17 (2023)
Sungyeun Bae, JungJin Oh, Ildae Song, Kyung-Sang Yu, Seung Hwan Lee
Considerations for clinical evaluation of the effects of bariatric surgery on the pharmacokinetics of orally administered drugs. Translational and clinical pharmacology 30 (3) (2022)